Morgan Stanley Global Healthcare Conference

September 13, 2010
New York, NY
This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.

Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company’s financial results is included in the Company’s Form 10-K for the year ended December 31, 2009, and subsequent SEC filings.
Leading National Lab Provider

- Fastest growing national lab
- $55 billion market
- Clinical, Anatomic and Genomic Testing
- Serving clients in all 50 states and Canada
- Foremost clinical trials testing business
Introduction

Laboratory Testing

- Prevention and Wellness Monitoring
- Preliminary Risk Assessment
- Diagnosis
- Secondary Assessment of Prognosis
- Clinical Decision Regarding Treatment Path
- Monitoring and Management of Condition

Health Care Continuum

Source: Deloitte (OAML)
Valuable Service

• Small component of total cost influences large percentage of clinical decisions
• Screening, early detection, and monitoring reduce downstream costs
• Companion diagnostics improve drug efficacy and reduce adverse drug effects

2009 Projected US Health Care Spend $2.5 Trillion

- 2-3% of spend influences 70-80% of physician decisions

Attractive Market

Growth Drivers

- Aging population
- Industry consolidation
- Advances in genomics
- Pharmacogenomics / companion diagnostics
- Cost pressures

Source: CDC National Ambulatory Medical Care Survey and Company Estimates
Opportunity to Take Share

- Approximately 5,000 independent labs
- High cost competitors

$55 Billion US Lab Market

Source: Washington G-2 Reports and company estimates
Attractive Market

Diversified Payor Mix

- No customer > 9% of revenue
- Limited government exposure

LabCorp U.S. Payor Mix
% of revenue, 2009

- Medicare and Medicaid: 20.2%
- Managed Care Capitated: 27.1%
- Managed Care Fee-for-service: 7.6%
- Client (physicians, hospitals, companies, etc): 41.3%
Diversified Test Mix

- Esoteric 36% of revenue
- Goal of 40% in 3 – 5 years
- Higher priced business

LabCorp U.S. Test Mix
% of revenue, 2009

- 64.0% Core
- 15.7% All Genomic
- 13.7% Histology
- 6.6% Other Esoteric
Scale and Scope

- National infrastructure
- Broad test offering
- Managed care contracts
- Economies of scale

Primary LabCorp Testing Locations*

Patient Service Centers*

Primary LabCorp Testing Locations*

Esoteric Lab Locations
(CET, CMBP, Dianon, Esoterix, Monogram Biosciences, NGI, OTS, US Labs, Viromed)
Managed Care Relationships

- Exclusive national laboratory for UnitedHealthcare
- Sole national strategic partner for WellPoint
- Significant national plans recently renewed or extended on a multi-year basis, including WellPoint, Cigna and Humana
- Contracted with numerous local and regional anchor plans
Scientific Leadership

- Introduction of new tests
- Acquisitions and licensing
- Collaborations with leading companies and academic institutions

<table>
<thead>
<tr>
<th>Partner</th>
<th>Clinical Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARCA biopharma</td>
<td>Companion Diagnostics (CVD) (exclusive)</td>
</tr>
<tr>
<td>Celera Diagnostics</td>
<td>Breast Cancer</td>
</tr>
<tr>
<td>Duke University</td>
<td>Lung Cancer (exclusive)</td>
</tr>
<tr>
<td>Exact Sciences</td>
<td>Colon Cancer</td>
</tr>
<tr>
<td>Intema Ltd.</td>
<td>Prenatal Testing</td>
</tr>
<tr>
<td>Ipsogen</td>
<td>Molecular Diagnostics</td>
</tr>
<tr>
<td>Medco Health Solutions</td>
<td>Companion Diagnostics (Research)</td>
</tr>
<tr>
<td>OncoMethylome Sciences</td>
<td>Companion Diagnostics (Oncology) (exclusive)</td>
</tr>
<tr>
<td>Siemens Health Solutions</td>
<td>Companion Diagnostics (Oncology and CVD)</td>
</tr>
<tr>
<td>SmartGene</td>
<td>Bioinformatics Tools</td>
</tr>
<tr>
<td>Third Wave Technologies</td>
<td>Companion Diagnostics (CVD)</td>
</tr>
<tr>
<td>Vanda Pharmaceuticals</td>
<td>Companion Diagnostics (exclusive)</td>
</tr>
<tr>
<td>Veridex</td>
<td>Prostate Cancer</td>
</tr>
<tr>
<td>Yale University</td>
<td>Ovarian Cancer (exclusive)</td>
</tr>
</tbody>
</table>
Competitive Position

Standardized and Efficient Processes

- Standardized lab and billing IT systems
- Automation of pre-analytics
- Capacity rationalization
- Logistics optimization
Our Focus

• Profitable revenue growth
• IT and client connectivity
• Continue scientific leadership
• Maintain price
• Control costs
Our Results

• Profitable revenue growth
  • Empire contract
  • Esoteric growth
  • Acquisitions
• Improved IT and client connectivity
  • LabCorp Beacon
  • Enhanced experience for physicians and patients
• Continued scientific leadership
  • Clearstone collaboration
  • IL-28B
  • New Monogram assays
• Maintained price
  • Managed care stability
  • Strong 1H 2010 results
• Controlled costs
  • Gross margin expansion
  • Sysmex project
2010 Accomplishments

**Profitable Revenue Growth**

- Empire contract
  - In network status as of Aug 1, 2010
  - New York’s largest insurer by membership
- Esoteric revenue growth
  - 5.1% growth in first half of 2010
  - Expansion of Monogram offerings
- Acquisitions
  - Westcliff
  - DCL
- 3.7% total revenue growth in first half of 2010
  - Challenging economic environment
  - Positive volume growth, after adjusting for lost contracts
2010 Accomplishments

**Improved IT and Client Connectivity**
- LabCorp Beacon: A superior physician experience
- Intuitive Orders and Results
  - Unread reports in bold while abnormal values are displayed in red
  - Share results via Email, Fax and Print
  - Group patients according to a client’s needs
- Add notes to any report to share critical insights
Improved IT and Client Connectivity

- Powerful Analytics
- Graphical views of a patient over time
- Generate trends and averages for large populations
Continued Scientific Leadership

- Clearstone collaboration
  - Global clinical trials capability
  - Presence in China
- Enhanced offerings in companion diagnostics and personalized medicine
  - IL-28B
  - K-RAS
  - HLA-B* 5701
  - BRAF Gene Mutation Detection
  - EGFR Mutation Analysis
  - CYP 450 2C19
  - Trofile (CCR5 Trophism)
  - PhenoSense, PhenoSense GT
  - HerMark
- Grew Outcome Improvement Programs
  - Relaunch of CKD program
  - Litholink kidney stone program

“K-RAS testing should be routinely conducted in all colorectal cancer patients immediately after diagnosis to ensure the best treatment strategies for the individual Patient”

– Dr. Eric Van Cutsem, presenter at the June 2008 American Society of Clinical Oncology meeting

FDA recommends genetic screening prior to treatment with Abacavir

ROCKVILLE, Md -- July 24, 2008 -- The US Food and Drug Administration (FDA) has issued an alert regarding serious, and sometimes fatal, hypersensitivity reactions (HSRs) caused by abacavir (Ziagen) therapy in patients with a particular human leukocyte antigen (HLA) allele, HLA-B* 5701.

Genetic tests for HLA-B*5701 are already available, and all patients should be screened for the HLA-B*5701 allele before starting or restarting treatment with abacavir or abacavir-containing medications.

“FDA has approved the expanded use of Selzentry… to include adult patients with CCR5-tropic HIV-1 virus who are starting treatment for the first time.”

2010 Accomplishments

Maintained Price
- Managed care stability
- Pricing discipline has offset 1.9% Medicare rate decrease
- Promoted high-value tests
- Other recent benefits
  - Monogram
  - Canadian exchange rate
  - Impact from lost government contracts

Selected Financial Data

The selected financial data presented below under the captions “Statement of Operations Data” of and for the five-year period ended December 31, 2009 are derived from consolidated financial statements which have been audited by an independent registered public accounting firm. This data should be read in conjunction with the accompanying notes, the Company’s consolidated financial statements and the related notes to those statements discussed in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” all included elsewhere in this report.

<table>
<thead>
<tr>
<th>Year Ended December</th>
<th>2009(a)</th>
<th>2008(b)</th>
<th>2007(c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(In millions, except per share amounts)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Statement of Operations Data:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net sales</td>
<td>$4,694.7</td>
<td>$4,505.2</td>
<td>$4,068.2</td>
</tr>
<tr>
<td>Gross profit</td>
<td>$1,970.9</td>
<td>$1,873.8</td>
<td>$1,691.2</td>
</tr>
<tr>
<td>Operating income</td>
<td>$935.9</td>
<td>$842.9</td>
<td>$777.0</td>
</tr>
<tr>
<td>Net earnings attributable to</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory Corporation of America Holdings</td>
<td>$543.3</td>
<td>$464.5</td>
<td>$476.8</td>
</tr>
<tr>
<td>Basic earnings per common share</td>
<td>$5.06</td>
<td>$4.23</td>
<td>$4.08</td>
</tr>
</tbody>
</table>
Controlled Costs

- Y/Y gross margin improvement for three consecutive quarters
- Sysmex contract
  - Fully automated hematology operations
  - One of largest lab automation projects ever undertaken
- Bad debt reduction of 50bp in the first half of 2010
- Continued to optimize supply chain
- Used efficiency gains to improve physician and patient experiences
Excellent Performance

Revenue and EPS Growth

- 9% Revenue CAGR
- 15% EPS CAGR


(1) Excluding the $0.09 per diluted share impact in 2005 of restructuring and other special charges, and a non-recurring investment loss; excluding the $0.06 per diluted share impact in 2006 of restructuring and other special charges; excluding the $0.25 per diluted share impact in 2007 of restructuring and other special charges; excluding the $0.44 per diluted share impact in 2008 of restructuring and other special charges; excluding the ($0.09) per diluted share impact in 2009 of restructuring and other special charges.

(2) EPS, as presented, represents adjusted, non-GAAP financial measures. Diluted EPS, as reported in the Company’s Annual Report were: $2.45 in 2004; $2.71 in 2005; $3.24 in 2006; $3.93 in 2007; $4.16 in 2008; and $4.98 in 2009.
Leading Returns

- Leading returns
- Leading EBIT margin

LabCorp ROE 2004 - 2009

<table>
<thead>
<tr>
<th>Year</th>
<th>ROE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>18.2%</td>
</tr>
<tr>
<td>2005</td>
<td>20.5%</td>
</tr>
<tr>
<td>2006</td>
<td>21.8%</td>
</tr>
<tr>
<td>2007</td>
<td>27.6%</td>
</tr>
<tr>
<td>2008</td>
<td>27.5%</td>
</tr>
<tr>
<td>2009</td>
<td>25.8%</td>
</tr>
</tbody>
</table>
Excellent Performance

Cash Flow

- 11% FCF CAGR
- $2.0 B+ share repurchase over last three years

Note: $ in Millions
## Second Quarter and YTD 2010 Results

<table>
<thead>
<tr>
<th></th>
<th>Three Months Ended Jun 30,</th>
<th></th>
<th>Six Months Ended Jun 30,</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2010</td>
<td>2009</td>
<td>+/-</td>
<td>2010</td>
</tr>
<tr>
<td>Revenue (1)</td>
<td>$ 1,238.4</td>
<td>$ 1,188.8</td>
<td>4.2%</td>
<td>$ 2,432.0</td>
</tr>
<tr>
<td>Adjusted Operating Income</td>
<td>$ 270.5</td>
<td>$ 254.9</td>
<td>6.1%</td>
<td>$ 514.0</td>
</tr>
<tr>
<td>Adjusted Operating Income Margin</td>
<td>21.8%</td>
<td>21.4%</td>
<td>40 bp</td>
<td>21.1%</td>
</tr>
<tr>
<td>Adjusted EPS (1)</td>
<td>$ 1.46</td>
<td>$ 1.30</td>
<td>12.3%</td>
<td>$ 2.76</td>
</tr>
<tr>
<td>Operating Cash Flow</td>
<td>$ 216.2</td>
<td>$ 182.4</td>
<td>18.5%</td>
<td>$ 448.2</td>
</tr>
<tr>
<td>Less: Capital Expenditures</td>
<td>$ (34.5)</td>
<td>$ (23.7)</td>
<td>45.6%</td>
<td>$ (59.0)</td>
</tr>
<tr>
<td>Free Cash Flow</td>
<td>$ 181.7</td>
<td>$ 158.7</td>
<td>14.5%</td>
<td>$ 389.2</td>
</tr>
</tbody>
</table>

(1) During the first quarter inclement weather reduced revenue by an estimated $23 million and EPS by approximately eight cents
### Reconciliation of non-GAAP Financial Measures

(In millions, except per share data)

<table>
<thead>
<tr>
<th></th>
<th>Three Months Ended June 30, 2010</th>
<th></th>
<th>Six Months Ended June 30, 2010</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>2009</td>
<td>2010</td>
<td>2009</td>
</tr>
<tr>
<td>Adjusted Operating Income</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operating income</td>
<td>$ 270.5</td>
<td>$ 244.7</td>
<td>$ 504.7</td>
<td>$ 485.2</td>
</tr>
<tr>
<td>Restructuring and other special charges</td>
<td>$ -</td>
<td>$ 10.2</td>
<td>$ 9.3</td>
<td>$ 10.2</td>
</tr>
<tr>
<td>Adjusted operating income</td>
<td></td>
<td>$ 270.5</td>
<td>$ 254.9</td>
<td>$ 514.0</td>
</tr>
<tr>
<td>Adjusted EPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diluted earnings per common share</td>
<td>$ 1.46</td>
<td>$ 1.24</td>
<td>$ 2.70</td>
<td>$ 2.46</td>
</tr>
<tr>
<td>Impact of restructuring and other special charges (1) (2)</td>
<td>$ -</td>
<td>$ 0.06</td>
<td>$ 0.06</td>
<td>$ 0.05</td>
</tr>
<tr>
<td>Adjusted EPS</td>
<td></td>
<td>$ 1.46</td>
<td>$ 1.30</td>
<td>$ 2.76</td>
</tr>
</tbody>
</table>

(1) After tax impact of restructuring and other special charges for the three months and six months ended June 30, 2010 ($- million divided by 105.4 million shares and $5.7 million divided by 105.9 million shares, respectively)

(2) After tax impact of restructuring and other special charges for the three months and six months ended June 30, 2009 ($6.0 million divided by 109.5 and 109.4 million shares, respectively)
# Laboratory Corporation of America

## Other Financial Information

FY 2009 and Q1/Q2 2010

($ in millions)

<table>
<thead>
<tr>
<th></th>
<th>Q1 09</th>
<th>Q2 09</th>
<th>Q3 09</th>
<th>Q4 09</th>
<th>Q1 10</th>
<th>Q2 10</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bad debt as a percentage of sales</strong></td>
<td>5.30%</td>
<td>5.30%</td>
<td>5.30%</td>
<td>5.30%</td>
<td>5.05%</td>
<td>4.80%</td>
</tr>
<tr>
<td><strong>Days sales outstanding</strong></td>
<td>52</td>
<td>50</td>
<td>48</td>
<td>44</td>
<td>46</td>
<td>45</td>
</tr>
<tr>
<td><strong>A/R coverage (Allow. for Doubtful Accts. / A/R)</strong></td>
<td>19.5%</td>
<td>20.6%</td>
<td>21.9%</td>
<td>23.2%</td>
<td>21.7%</td>
<td>20.7%</td>
</tr>
</tbody>
</table>
Key Points
- Critical position in health care delivery system
- Attractive market
- Strong competitive position - well positioned to gain share
- Leadership in personalized medicine
- Excellent cash flow
- Strong balance sheet

Laboratory Testing

Health Care Continuum

Source: Deloitte (OAML)